Gb Sciences Inc (OTCMKTS:GBLX) Stock Falls 30% in a Month: Here is Why

In the past month the Gb Sciences Inc (OTCMKTS:GBLX) stock may have performed poorly and clocked declines of as much as 31% during the period. However, the stock could be back in focus today after the company made a major announcement.

The company announced this morning that it received the proof of concept data with regards to its Cytokine release syndrome therapies that are meant for suppressing hyperinflammation brought about by COVID 19 infection. The proof of concept data that was received by Gb Sciences has been positive and that could result in renewed focus on the stock in the coming days.

After the company had received new proof of concept data for its therapies, it had actually changed its provisional patent application to a non-provisional one on August 18, 2021.

The original patent had been titled “CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS”. The latest proof of concept study into these therapies was performed at the Michigan State University by deploying a human immune model. This is a significant new development for the company and one that could have long term ramifications for Gb Sciences’ business.